World's Best Scientists 2026 revealed!
Michael Lübbert

Michael Lübbert

D-Index & Metrics

Medicine

D-Index
93
Citations
33140
World Ranking
10857
National Ranking
590

Michael Lübbert publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael Lübbert sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 530 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael Lübbert D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael Lübbert sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael Lübbert is affiliated with the University of Freiburg in Germany. Their research primarily focuses on medicine, with significant interdisciplinary contributions in biochemistry, genetics, and molecular biology. Within these fields, Lübbert's work centers on hematology and molecular biology, with additional focus on genetics, public health, environmental and occupational health, and cancer research.

The research topics covered by Lübbert include acute myeloid leukemia (AML) research, epigenetics and DNA methylation, histone deacetylase inhibitors research, acute lymphoblastic leukemia research, retinoids in leukemia and cellular processes, protein degradation and inhibitors, and chronic myeloid leukemia treatments.

Several frequent co-authors have collaborated extensively with Lübbert, including Konstanze Döhner, Hartmut Döhner, Michael Heuser, Arnold Ganser, and Felicitas Thol.

Lübbert has published extensively in various academic journals. The most common publication venues include Blood, Blood Advances, Leukemia, Annals of Hematology, and Clinical Lymphoma Myeloma & Leukemia.

Among recent papers authored or co-authored by Lübbert, the following are notable:

  • Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies, 2021, Leukemia
  • Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin, 2021, Blood
  • Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation, 2020, Nature Communications
  • Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans, 2020, Science Translational Medicine
  • Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial, 2020, Blood

Best Publications

  • Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

    F. Lo-Coco;G. Avvisati;M. Vignetti;C. Thiede

  • New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

    Detlef Haase;Ulrich Germing;Julie Schanz;Michael Pfeilstöcker

  • Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients

    P Wijermans;M Lübbert;Gregor Verhoef;A Bosly

  • Acute myeloid leukemia: epidemiology and etiology.

    Barbara Deschler;Michael Lübbert

  • Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

    Michael Lübbert;Stefan Suciu;Liliana Baila;Björn Hans Rüter

  • Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment

    Michael Daskalakis;Tudung T. Nguyen;Carvell Nguyen;Per Guldberg

  • TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.

    Frank G. Rücker;Richard F. Schlenk;Lars Bullinger;Sabine Kayser

  • DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.

    Giuseppe Leone;Luciana Teofili;Maria Teresa Voso;Michael Lübbert

  • Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

    R. Zeiser;A. Burchert;C. Lengerke;M.M. Verbeek

  • New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

    Julie Schanz;Heinz Tüchler;Francesc Solé;Mar Mallo

  • A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    Pierre Fenaux;Aristoteles Giagounidis;Dominik Selleslag;Odile Beyne-Rauzy

  • Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia

    Felicitas Thol;Frederik Damm;Andrea Lüdeking;Claudia Winschel

  • Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

    Jan Krönke;Richard F. Schlenk;Kai-Ole Jensen;Florian Tschürtz

  • Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

    Richard F Schlenk;Sabine Kayser;Lars Bullinger;Guido Kobbe

  • Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

    Julia M. Wagner;Björn Hackanson;Michael Lübbert;Manfred Jung

  • Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

    Uwe Platzbecker;Giuseppe Avvisati;Laura Cicconi;Christian Thiede

  • Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy

    Ludovica Morera;Michael Lübbert;Manfred Jung

  • CXCR4 is a prognostic marker in acute myelogenous leukemia

    Anke C. Spoo;Michael Lübbert;William G. Wierda;Jan A. Burger

  • The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.

    C. Flotho;R. Claus;C. Batz;M. Schneider

  • Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor

    Katharina Wagner;Frederik Damm;Gudrun Göhring;Kerstin Görlich

Frequent Co-Authors

Arnold Ganser
Arnold Ganser Hannover Medical School
Richard F. Schlenk
Richard F. Schlenk University Hospital Heidelberg
Hartmut Döhner
Hartmut Döhner University of Ulm
Ulrich Germing
Ulrich Germing Heinrich Heine University Düsseldorf
Konstanze Döhner
Konstanze Döhner University of Ulm
Michael Heuser
Michael Heuser Hannover Medical School
Aristoteles Giagounidis
Aristoteles Giagounidis Heinrich Heine University Düsseldorf
Oliver G. Ottmann
Oliver G. Ottmann Cardiff University
Peter Valent
Peter Valent Medical University of Vienna
Dietmar Pfeifer
Dietmar Pfeifer University of Freiburg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or complementary educational routes can enhance your medical career prospects in the USA. For students interested in the business side of healthcare, pursuing a health care administration online degree provides essential leadership and management skills. These programs often cover healthcare laws, policies, and operational practices, preparing graduates for a wide range of administrative roles.

Advancing your credentials with a master’s degree is also highly valued. The cheapest online mha programs make it easier for working professionals to elevate their expertise and qualify for higher-level administrative positions, all with flexible scheduling and reduced tuition costs.

For those aiming for clinical and academic leadership, there are cheap online dnp programs (Doctor of Nursing Practice) that focus on evidence-based care and advanced practice roles. Alternatively, pharmacy professionals can gain their credentials through accredited online pharmacy schools, allowing them to study at their own pace while accessing the latest advances in pharmaceutical sciences.

These flexible online programs can open additional pathways in healthcare, allowing you to tailor your studies to fit your career aspirations and lifestyle.

Best Scientists Citing Michael Lübbert

Trending Scientists

Recently Published Articles